Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07581821 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a prospective, single-arm Phase 2 study to evaluate the efficacy and safety of sintilimab combined with anlotinib and taxane-based chemotherapy in patients with recurrent (not unable to locally curative treatment) or metastatic NPC who failed at least first-line platinum-containing standard regimen and/or anti PD-1/L1.
Trial Details
NCT Number NCT07581821
Lead Sponsor Ming-Yuan Chen
Conditions
(from sponsor)		 Recurrent or Metastatic Nasopharyngeal Carcinoma
Related terms Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov